2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation

BACKGROUND: Baricitinib and tocilizumab are potent immunomodulators that can reduce mortality in severe and critical COVID-19. The objective of this study was to compare the outcomes of patients with COVID-19 who were treated with either baricitinib or tocilizumab. METHODS: This was a single-center,...

Descripción completa

Detalles Bibliográficos
Autores principales: Radziszewski, Skyler, Swamy, Siddharth, Jain, Ruchi, Bicking, Keri, Nyirenda, Themba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679165/
http://dx.doi.org/10.1093/ofid/ofad500.2260

Ejemplares similares

Ejemplares similares